There are thousands of biotech companies all in search of continued value creation and successful exits, but only the ones who have compelling and convincing data can demand the outsized value and healthy returns for shareholders. Our expert panelists have enabled continued value creation and exits for biotech startups through strategic deals, IPOs and later stage private equity investment and will speak about the things they look for when supporting these startups to success.